Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

ELVN

Enliven Therapeutics Inc

Apr 26 • 04:00PM ET

17.18

Dollar change +0.40
Percentage change 2.38	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN IBB VTWO SCHA VHT IWC CNCR

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.18	Insider Own	45.90%	Shs Outstand	41.29M	Perf Week	-0.58%
Market Cap	804.20M	Forward P/E	-	EPS next Y	-2.83	Insider Trans	-7.51%	Shs Float	25.32M	Perf Month	-7.78%
Income	-71.58M	PEG	-	EPS next Q	-0.54	Inst Own	45.48%	Short Float	18.33%	Perf Quarter	7.51%
Sales	0.00M	P/S	-	EPS this Y	-14.08%	Inst Trans	-9.24%	Short Ratio	17.73	Perf Half Y	40.82%
Book/sh	5.96	P/B	2.88	EPS next Y	-23.60%	ROA	-39.35%	Short Interest	4.64M	Perf Year	-11.90%
Cash/sh	5.41	P/C	3.18	EPS next 5Y	-	ROE	-42.61%	52W Range	9.80 - 26.00	Perf YTD	24.13%
Dividend Est.	-	P/FCF	-	EPS past 5Y	5.16%	ROI	-29.11%	52W High	-33.92%	Beta	1.05
Dividend TTM	-	Quick Ratio	10.28	Sales past 5Y	0.00%	Gross Margin	-	52W Low	75.31%	ATR (14)	1.81
Dividend Ex-Date	-	Current Ratio	10.28	EPS Y/Y TTM	-1063.16%	Oper. Margin	0.00%	RSI (14)	46.97	Volatility	6.51% 10.08%
Employees	46	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	34.33
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-109.62%	Payout	-	Rel Volume	0.57	Prev Close	16.78
Sales Surprise	-	EPS Surprise	12.43%	Sales Q/Q	-	Earnings	Mar 14 AMC	Avg Volume	261.66K	Price	17.18
SMA20	-8.18%	SMA50	0.36%	SMA200	13.96%	Trades		Volume	148,934	Change	2.38%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-09-24	Initiated	Mizuho	Buy	$34
Mar-29-23	Initiated	Jefferies	Buy	$27

Apr-19-24 03:03PM	MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-11-24 03:44PM	Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program (Benzinga) +20.18%
07:55AM	Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia (GlobeNewswire)
Apr-09-24 04:05PM	Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors (GlobeNewswire)
Mar-28-24 04:05PM	Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024 (GlobeNewswire) -5.58%
01:51AM	Loading…
Mar-23-24 01:51AM	Enliven Therapeutics Inc Director Rahul Ballal Sells 13,278 Shares (GuruFocus.com)
Mar-19-24 08:30AM	Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates (GlobeNewswire) +38.77%
Mar-14-24 09:53PM	ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -5.95%
04:05PM	Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-27-24 04:05PM	Enliven Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference (GlobeNewswire)
Jan-03-24 09:01AM	Enliven Therapeutics Inc CFO Benjamin Hohl Sells 11,870 Shares (GuruFocus.com)
Nov-09-23 04:05PM	Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire) -7.97%
Aug-17-23 06:40AM	7 A-Rated Biotech Stocks for Your August Buy List (InvestorPlace) +6.00%
Aug-10-23 04:05PM	Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
May-31-23 04:55PM	Enliven Therapeutics to Present at Two Upcoming Investor Conferences (GlobeNewswire)
04:05PM	Loading…
May-11-23 04:05PM	Enliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial Results (GlobeNewswire)
Mar-24-23 06:30AM	7 Biotech Stocks Sitting in the Sweet Spot (InvestorPlace)

Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates. The company was founded by Sam S. Kintz, Joe P. Lyssikatos, and Anish Patel in June 2019 and is headquartered in Boulder, CO.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Heyman Richard A.	Director	Apr 15 '24	Sale	19.99	1,270	25,383	137,155	Apr 15 07:03 PM
Ballal Rahul D.	Director	Apr 11 '24	Option Exercise	13.21	53,400	705,266	75,741	Apr 12 06:23 PM
Kintz Samuel	PRESIDENT AND CEO	Apr 11 '24	Option Exercise	1.12	47,709	53,434	47,709	Apr 15 07:05 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Apr 11 '24	Option Exercise	2.48	20,000	49,600	20,000	Apr 15 07:02 PM
Patel Anish	CHIEF OPERATING OFFICER	Apr 11 '24	Option Exercise	2.48	14,903	36,959	17,500	Apr 15 07:06 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Apr 11 '24	Option Exercise	2.48	14,000	34,720	14,000	Apr 15 07:04 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Apr 11 '24	Option Exercise	1.12	30,000	33,600	30,000	Apr 15 07:06 PM
Ballal Rahul D.	Director	Apr 11 '24	Sale	23.95	53,400	1,279,068	22,341	Apr 12 06:23 PM
Kintz Samuel	PRESIDENT AND CEO	Apr 11 '24	Sale	25.04	47,709	1,194,700	0	Apr 15 07:05 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Apr 11 '24	Sale	25.04	30,000	751,332	0	Apr 15 07:06 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Apr 11 '24	Sale	25.07	20,000	501,478	0	Apr 15 07:02 PM
Patel Anish	CHIEF OPERATING OFFICER	Apr 11 '24	Sale	25.03	17,500	438,098	0	Apr 15 07:06 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Apr 11 '24	Sale	24.72	14,000	346,149	0	Apr 15 07:04 PM
Heyman Richard A.	Director	Apr 11 '24	Sale	25.03	5,045	126,279	138	Apr 15 07:03 PM
Heyman Richard A.	Director	Apr 11 '24	Sale	25.00	649	16,225	28,567	Apr 15 07:03 PM
Ballal Rahul D.	Director	Apr 10 '24	Option Exercise	12.60	13,600	171,360	35,941	Apr 12 06:23 PM
Ballal Rahul D.	Director	Apr 10 '24	Sale	21.01	13,600	285,744	22,341	Apr 12 06:23 PM
Patel Anish	CHIEF OPERATING OFFICER	Apr 08 '24	Sale	18.60	4,875	90,687	2,597	Apr 10 08:35 PM
Ballal Rahul D.	Director	Apr 04 '24	Option Exercise	12.60	3,485	43,911	25,826	Apr 08 08:40 PM
Ballal Rahul D.	Director	Apr 04 '24	Sale	19.15	3,485	66,729	22,341	Apr 08 08:40 PM
Ballal Rahul D.	Director	Apr 01 '24	Option Exercise	5.73	3,237	18,534	25,578	Apr 03 09:32 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Apr 01 '24	Option Exercise	1.12	12,000	13,440	12,000	Apr 03 09:30 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Apr 01 '24	Sale	18.60	12,000	223,146	0	Apr 03 09:30 PM
Ballal Rahul D.	Director	Apr 01 '24	Sale	19.08	3,237	61,758	22,341	Apr 03 09:32 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Mar 27 '24	Option Exercise	2.48	3,250	8,060	3,250	Mar 29 05:59 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Mar 27 '24	Sale	18.25	3,250	59,302	0	Mar 29 05:59 PM
Kintz Samuel	PRESIDENT AND CEO	Mar 25 '24	Option Exercise	1.12	12,000	13,440	12,000	Mar 27 05:03 PM
Kintz Samuel	PRESIDENT AND CEO	Mar 25 '24	Sale	17.56	12,000	210,661	0	Mar 27 05:03 PM
Ballal Rahul D.	Director	Mar 20 '24	Option Exercise	5.52	13,278	73,295	35,619	Mar 22 07:46 PM
Ballal Rahul D.	Director	Mar 20 '24	Sale	19.16	13,278	254,462	22,341	Mar 22 07:46 PM
Heyman Richard A.	Director	Mar 19 '24	Sale	14.50	1,270	18,419	143,470	Mar 21 06:41 PM
Patel Anish	CHIEF OPERATING OFFICER	Mar 06 '24	Sale	15.64	4,875	76,239	7,472	Mar 08 07:52 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Feb 29 '24	Option Exercise	1.12	12,000	13,440	12,000	Mar 04 05:55 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Feb 29 '24	Sale	16.42	12,000	197,006	0	Mar 04 05:55 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Feb 27 '24	Option Exercise	2.48	3,250	8,060	3,250	Feb 29 05:27 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Feb 27 '24	Sale	16.97	3,250	55,163	0	Feb 29 05:27 PM
Heyman Richard A.	Director	Feb 15 '24	Sale	17.42	1,270	22,117	144,740	Feb 20 07:41 PM
5AM Partners VI, LLC	10% Owner	Feb 14 '24	Sale	14.90	825,000	12,292,500	635,341	Feb 16 04:15 PM
Patel Anish	CHIEF OPERATING OFFICER	Feb 06 '24	Sale	15.11	4,875	73,658	12,347	Feb 08 08:47 PM
5AM Partners VI, LLC	10% Owner	Jan 31 '24	Sale	15.00	500,000	7,500,000	771,983	Feb 02 04:29 PM
Heyman Richard A.	Director	Jan 30 '24	Sale	16.41	1,270	20,840	146,010	Feb 01 08:10 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Jan 29 '24	Option Exercise	1.12	12,000	13,440	12,000	Jan 31 09:22 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jan 29 '24	Option Exercise	2.48	3,250	8,060	3,250	Jan 31 09:20 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Jan 29 '24	Sale	15.85	12,000	190,256	0	Jan 31 09:22 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jan 29 '24	Sale	15.81	3,250	51,388	0	Jan 31 09:20 PM
Kintz Samuel	President and CEO	Jan 25 '24	Option Exercise	1.12	12,000	13,440	12,000	Jan 29 08:01 PM
Kintz Samuel	President and CEO	Jan 25 '24	Sale	15.69	12,000	188,229	0	Jan 29 08:01 PM
Patel Anish	Chief Operating Officer	Jan 22 '24	Sale	15.13	4,875	73,783	17,222	Jan 24 06:38 PM
Hohl Benjamin	Chief Financial Officer	Jan 02 '24	Option Exercise	2.48	9,383	23,270	9,383	Jan 02 07:59 PM
Patel Anish	Chief Operating Officer	Jan 02 '24	Sale	15.00	11,000	165,053	22,097	Jan 02 08:00 PM
Hohl Benjamin	Chief Financial Officer	Jan 02 '24	Sale	15.01	9,383	140,839	0	Jan 02 07:59 PM
Lyssikatos Joseph P	Chief Scientific Officer	Dec 29 '23	Option Exercise	1.12	12,000	13,440	12,000	Jan 03 07:01 PM
Hohl Benjamin	Chief Financial Officer	Dec 29 '23	Option Exercise	2.48	20	50	20	Jan 02 07:59 PM
Lyssikatos Joseph P	Chief Scientific Officer	Dec 29 '23	Sale	14.28	12,000	171,381	0	Jan 03 07:01 PM
Patel Anish	Chief Operating Officer	Dec 29 '23	Sale	15.00	20	300	33,097	Jan 02 08:00 PM
Hohl Benjamin	Chief Financial Officer	Dec 29 '23	Sale	15.00	20	300	0	Jan 02 07:59 PM
Hohl Benjamin	Chief Financial Officer	Dec 28 '23	Option Exercise	2.48	2,467	6,118	2,467	Jan 02 07:59 PM
Patel Anish	Chief Operating Officer	Dec 28 '23	Sale	15.08	2,520	37,996	33,117	Jan 02 08:00 PM
Hohl Benjamin	Chief Financial Officer	Dec 28 '23	Sale	15.07	2,467	37,188	0	Jan 02 07:59 PM
Kintz Samuel	President and CEO	Dec 26 '23	Option Exercise	1.12	12,000	13,440	12,000	Dec 28 04:29 PM
Hohl Benjamin	Chief Financial Officer	Dec 26 '23	Option Exercise	2.48	100	248	100	Dec 27 05:26 PM
Kintz Samuel	President and CEO	Dec 26 '23	Sale	14.64	12,000	175,709	0	Dec 28 04:29 PM
Patel Anish	Chief Operating Officer	Dec 26 '23	Sale	15.01	102	1,531	35,637	Dec 27 05:28 PM
Hohl Benjamin	Chief Financial Officer	Dec 26 '23	Sale	15.00	100	1,500	0	Dec 27 05:26 PM
Kintz Samuel	President and CEO	Dec 22 '23	Option Exercise	1.12	8,175	9,156	8,175	Dec 26 07:31 PM
Lyssikatos Joseph P	Chief Scientific Officer	Dec 22 '23	Option Exercise	1.12	6,546	7,332	6,546	Dec 26 07:32 PM
Hohl Benjamin	Chief Financial Officer	Dec 22 '23	Option Exercise	2.48	1,030	2,554	1,030	Dec 27 05:26 PM
Kintz Samuel	President and CEO	Dec 22 '23	Sale	13.05	8,175	106,655	0	Dec 26 07:31 PM
Lyssikatos Joseph P	Chief Scientific Officer	Dec 22 '23	Sale	13.07	6,546	85,530	0	Dec 26 07:32 PM
Hohl Benjamin	Chief Financial Officer	Dec 22 '23	Sale	15.07	1,030	15,525	0	Dec 27 05:26 PM
Patel Anish	Chief Operating Officer	Dec 22 '23	Sale	15.03	983	14,776	35,739	Dec 27 05:28 PM
Heyman Richard A.	Director	Dec 22 '23	Sale	13.00	168	2,184	147,280	Dec 26 07:29 PM
Heyman Richard A.	Director	Dec 22 '23	Sale	13.00	35	455	29,216	Dec 26 07:29 PM
Kintz Samuel	President and CEO	Dec 21 '23	Option Exercise	1.12	20	22	20	Dec 26 07:31 PM
Lyssikatos Joseph P	Chief Scientific Officer	Dec 21 '23	Option Exercise	1.12	20	22	20	Dec 26 07:32 PM
Lyssikatos Joseph P	Chief Scientific Officer	Dec 21 '23	Sale	13.00	20	260	0	Dec 26 07:32 PM
Kintz Samuel	President and CEO	Dec 21 '23	Sale	13.00	20	260	0	Dec 26 07:31 PM
Heyman Richard A.	Director	Dec 21 '23	Sale	13.00	7	91	147,448	Dec 26 07:29 PM
Heyman Richard A.	Director	Dec 21 '23	Sale	13.00	6	78	29,251	Dec 26 07:29 PM
Lyssikatos Joseph P	Chief Scientific Officer	Dec 20 '23	Option Exercise	1.12	8,688	9,731	8,688	Dec 21 04:29 PM
Kintz Samuel	President and CEO	Dec 20 '23	Option Exercise	1.12	7,779	8,712	7,779	Dec 21 04:31 PM
Lyssikatos Joseph P	Chief Scientific Officer	Dec 20 '23	Sale	13.01	8,688	113,046	0	Dec 21 04:29 PM
Kintz Samuel	President and CEO	Dec 20 '23	Sale	13.01	7,779	101,238	0	Dec 21 04:31 PM
Heyman Richard A.	Director	Dec 20 '23	Sale	13.02	2,110	27,473	147,455	Dec 21 04:28 PM
Heyman Richard A.	Director	Dec 20 '23	Sale	13.02	1,915	24,939	29,257	Dec 21 04:28 PM
Lyssikatos Joseph P	Chief Scientific Officer	Dec 19 '23	Option Exercise	1.12	200	224	200	Dec 21 04:29 PM
Heyman Richard A.	Director	Dec 19 '23	Sale	13.00	255	3,315	149,565	Dec 21 04:28 PM
Lyssikatos Joseph P	Chief Scientific Officer	Dec 19 '23	Sale	13.00	200	2,600	0	Dec 21 04:29 PM
Lyssikatos Joseph P	Chief Scientific Officer	Nov 03 '23	Option Exercise	1.12	8,546	9,572	8,546	Nov 06 04:43 PM
Kintz Samuel	President and CEO	Nov 03 '23	Option Exercise	1.12	8,026	8,989	8,026	Nov 06 04:42 PM
Lyssikatos Joseph P	Chief Scientific Officer	Nov 03 '23	Sale	13.08	8,546	111,751	0	Nov 06 04:43 PM
Kintz Samuel	President and CEO	Nov 03 '23	Sale	13.08	8,026	104,999	0	Nov 06 04:42 PM
Lyssikatos Joseph P	Chief Scientific Officer	Sep 29 '23	Option Exercise	1.12	12,000	13,440	12,000	Oct 03 07:40 PM
Lyssikatos Joseph P	Chief Scientific Officer	Sep 29 '23	Sale	13.62	12,000	163,498	0	Oct 03 07:40 PM
5AM Partners VI, LLC	10% Owner	Sep 26 '23	Sale	15.00	197,500	2,962,500	854,796	Sep 28 04:27 PM
Kintz Samuel	President and CEO	Sep 25 '23	Option Exercise	1.12	12,000	13,440	12,000	Sep 26 07:37 PM
Kintz Samuel	President and CEO	Sep 25 '23	Sale	13.81	12,000	165,691	0	Sep 26 07:37 PM
5AM Partners VI, LLC	10% Owner	Aug 24 '23	Sale	16.00	440,000	7,040,000	887,507	Aug 28 04:20 PM
Gupta Rishi	Director	May 17 '23	Option Exercise	4.28	2,125	9,095	8,663,349	May 19 04:12 PM
ORBIMED ADVISORS LLC	Director	May 17 '23	Option Exercise	4.28	2,125	9,095	8,663,349	May 19 04:19 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ELVN

Enliven Therapeutics Inc

Upgrade your FINVIZ experience